amprenavir has been researched along with brecanavir in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carter, HL; Danger, D; Furfine, ES; Hanlon, MH; Kaldor, IW; Miller, JF; Porter, DJ; Samano, VA; Shu, AY; Spaltenstein, A | 1 |
| Andrews, CW; Brieger, M; Furfine, ES; Hale, MR; Hanlon, MH; Hazen, RJ; Kaldor, I; McLean, EW; Miller, JF; Reynolds, D; Sammond, DM; Sherrill, RG; Spaltenstein, A; Tung, R; Turner, EM; Xu, RX | 1 |
| Boone, L; Craig, C; Ferris, R; Furfine, E; Griffin, P; Hale, M; Hanlon, M; Harvey, R; Hazen, R; Kaldor, I; Miller, J; Ray, J; Samano, V; Spaltenstein, A; St Clair, M; Tung, R; Yates, P | 1 |
| Babusis, D; Bhoopathy, S; Hidalgo, IJ; Phan, TK; Ray, AS; Rhodes, GR; Robinson, KL; Strab, R; Tong, L | 1 |
| Boucher, MJ; Brynda, J; Craik, CS; Drąg, M; Grzymska, J; Hájek, M; Hradilek, M; Konvalinka, J; Kryštůfek, R; Madhani, HD; Majer, P; Řezáčová, P; Rut, W; Šácha, P; Starková, J; Tloušt'ová, E | 1 |
5 other study(ies) available for amprenavir and brecanavir
| Article | Year |
|---|---|
Inhibition of wild-type and mutant human immunodeficiency virus type 1 proteases by GW0385 and other arylsulfonamides.
Topics: Amino Acid Substitution; Binding, Competitive; Carbamates; Chromatography, Affinity; Chromatography, Gel; Dextrans; Dimerization; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Hydrolysis; Kinetics; Protein Binding; Saquinavir; Spectrometry, Fluorescence; Substrate Specificity; Sulfonamides | 2004 |
Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385.
Topics: HIV Protease Inhibitors; Molecular Structure; Sulfonamides | 2006 |
In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.
Topics: Algorithms; Anti-Retroviral Agents; Benzodioxoles; Blood Proteins; Carbamates; Cell Line; Drug Resistance, Viral; HeLa Cells; HIV Protease Inhibitors; HIV-1; Humans; Orosomucoid; Phenotype; Serum; Serum Albumin; Tyrosine | 2007 |
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
Topics: Adenine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cell Line; Chromatography, High Pressure Liquid; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Interactions; Epithelium; HIV Protease Inhibitors; Humans; Hydrolysis; Indicators and Reagents; Intestinal Absorption; Mass Spectrometry; Organophosphonates; Subcellular Fractions; Tenofovir | 2007 |
Re-emerging Aspartic Protease Targets: Examining
Topics: Antifungal Agents; Aspartic Acid Proteases; Binding Sites; Catalytic Domain; Cryptococcus neoformans; Crystallography, X-Ray; Drug Evaluation, Preclinical; Fungal Proteins; Fungi; HIV; HIV Protease; Molecular Dynamics Simulation; Recombinant Proteins; Structure-Activity Relationship; Substrate Specificity | 2021 |